The study is supported by the US Food and Drug Administration (FDA) and led by the Mayo Clinic, noted HCA Healthcare.

HCA Healthcare chief medical officer Dr Jonathan Perlin said: “As a learning healthcare system that serves communities across the country, we are proud to play a part in broader global public health initiatives, including this and other research, to identify effective Covid-19 treatments.

“We’re encouraging the communities HCA Healthcare serves to join us in this important effort to help identify donors.”

As a result of COVID-19, do you think that telehealth and virtual care technology adoption and usage will remain a staple of the healthcare sector after the pandemic has subsided?

Yes, and adoption and usage will continue to increase

Yes, but adoption and usage will slow down

No, the adoption and usage will only remain high during the COVID-19 pandemic

Sarah Cannon Research Institute, a clinical research organisation that performs community-based trials, is supporting HCA Healthcare’s participation in the Covid-19 study.

Sarah Cannon Research Institute clinical operations president and chief medical officer Howard Burris said: “We are aggressively working with our research partners to assess a variety of clinical studies for the diagnosis and treatment of Covid-19.

“The convalescent plasma study is focused on treating patients currently facing severe cases of Covid-19, by arming their immune systems with plasma that is rich in virus-fighting antibodies from individuals who have recently recovered.”

Previously, convalescent plasma was used to help prevent and treat infection during outbreaks of other coronaviruses, including such as SARS-1 and Middle East Respiratory Syndrome (MERS).

RECOMMENDED COMPANIES

Learn more

Hover over the logos to learn more about the companies who made this project possible.